Pharmaceuticals

Vutrisiran Market Forecast 2026–2030 Presenting Long-Term Industry Insights

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Vutrisiran Market During 2026–2030?

The vutrisiran market has seen rapid expansion in recent years. It is forecast to rise from $0.67 billion in 2025 to $0.75 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 12.1%. This historical growth can be attributed to several factors, including landmark siRNA approvals, the substantial unmet needs present in hATTR amyloidosis, restrictions associated with liver transplant options, the expanding reach of orphan drug policies, and enhancements in genetic diagnosis.

The vutrisiran market is projected for substantial expansion in the upcoming years. It is anticipated to achieve a valuation of $1.18 billion by 2030, expanding at a compound annual growth rate (CAGR) of 12.0%. This growth during the forecast period is attributed to factors such as increasing rare disease awareness, the development of the RNA therapeutics pipeline, the rising acceptance of long-acting treatments, enhanced genetic screening, and the expansion of specialty care centers. Prominent trends expected in the forecast period involve the growing adoption of RNA interference therapies, an increased emphasis on rare genetic disorders, the introduction of long-interval dosing treatments, a surging demand for targeted amyloidosis therapies, and the expanded use of subcutaneous RNA drugs.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21320&type=smp

What Significant Factors Are Influencing The Vutrisiran Market Expansion?

Higher investment in research and development is projected to propel the future expansion of the vutrisiran market. Research and development involves systematically investigating and experimenting to innovate and enhance products, services, or processes. This increased R&D funding results from government initiatives and support, the escalating needs of healthcare and pharmaceuticals, and sustainability and environmental considerations. R&D financing empowers pharmaceutical companies to conduct clinical trials, which demonstrate a drug’s long-term benefits and safety, leading to broader regulatory approvals. Additionally, advancements in RNA interference (RNAi) technology improve the drug’s precision, reducing side effects and increasing patient adoption. For instance, according to the Office for National Statistics in April 2025, the UK government’s net spending on research and development (R&D) reached approximately US $22.9 billion (£17.4 billion) in 2023, an increase from about US $20.0 billion (£16.1 billion) in 2022. Consequently, the growing investment in research and development is a key driver for the vutrisiran market’s growth.

What Segment Categories Shape The Vutrisiran Market Segment Landscape?

The vutrisiran market covered in this report is segmented –

1) By Drug Class: RNA Interference (RNAi) Therapeutics, GalNAc-Conjugated Nucleic Acid Drugs, Synthetic RNA-Based Therapeutics

2) By Route Of Administration: Injectable, Subcutaneous

3) By Patient Demographics: Adult, Geriatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By RNA Interference (RNAi) Therapeutics: Small Interfering RNA (siRNA) Drugs, Gene-Silencing RNA Therapies

2) By GalNAc-Conjugated Nucleic Acid Drugs: GalNAc-Conjugated siRNA Therapies, Hepatocyte-Targeted RNA Therapeutics

3) By Synthetic RNA-Based Therapeutics: Chemically Modified RNA Therapeutics, Long-Acting RNA Therapeutics

Which Trends Are Impacting The Progress Of The Vutrisiran Market?

Leading companies in the vutrisiran market are broadening its use into cardiomyopathy through regulatory approvals, such as supplemental indications for ATTR CM, aiming to enlarge the patient base and optimize long-term value. A supplemental new drug application (sNDA) is a regulatory submission that extends an approved drug’s utilization to new indications. For instance, in March 2025, Alnylam Pharmaceuticals, a US-based biotech company, obtained FDA approval for AMVUTTRA (vutrisiran) in adult patients experiencing transthyretin amyloidosis cardiomyopathy (ATTR-CM), making it the inaugural RNAi therapeutic authorized for both polyneuropathy and cardiomyopathy forms of the disease. Consequently, this expansion into cardiomyopathy stands as a pivotal trend propelling growth in the vutrisiran market, by enhancing its clinical reach and patient availability.

Who Are The Companies Operating Across The Vutrisiran Market Value Chain?

Major companies operating in the vutrisiran market are Alnylam Pharmaceuticals Inc

Get The Full Vutrisiran Market Report:

https://www.thebusinessresearchcompany.com/report/vutrisiran-global-market-report

Which Region Has The Greatest Market Share In The Vutrisiran Market?

North America was the largest region in the vutrisiran market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vutrisiran market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Vutrisiran Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/vutrisiran-global-market-report

Browse Through More Reports Similar to the Global Vutrisiran Market 2026, By The Business Research Company

Vulvodynia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report

Vasopressin Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasopressin-global-market-report

Vasodilators Market Report 2026

https://www.thebusinessresearchcompany.com/report/vasodilators-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795